Positive clinical trial data for SNG001, an inhaled formulation of interferon beta, in hospitalised COVID-19 patients

Preliminary data showed that risk of developing severe disease (requiring ventilation or resulting in death) during 16-day treatment period was reduced by 79% in patients receiving SNG001 vs placebo, with a higher rate of recovery and a reduced level of breathlessness.